509 results on '"Alexanian R"'
Search Results
2. CR represents an early index of potential long survival in multiple myeloma
Catalog
Books, media, physical & digital resources
3. International uniform response criteria for multiple myeloma
4. Clinical outcomes with intensive therapy for patients with primary resistant multiple myeloma
5. Outcomes of autologous stem cell transplantation in patients with multiple myeloma who received dexamethasone-based nonmyelosuppressive induction therapy
6. Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma
7. Impact of complete remission with intensive therapy in patients with responsive multiple myeloma
8. Thiotepa, busulfan, cyclophosphamide (TBC) and autologous hematopoietic transplantation: an intensive regimen for the treatment of multiple myeloma
9. Prognostic significance of magnetic resonance imaging of bone marrow in previously untreated patients with multiple myeloma
10. Long-term follow-up after high-dose therapy for high-risk multiple myeloma
11. Superior Outcomes with Recent Treatments for Myeloma: A028
12. Predictive Features for Long Survival in Multiple Myeloma: A035
13. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma
14. High-dose chemotherapy followed by stem cell transplantation in patients with resistant Waldenstrom's macroglobulinemia
15. Consolidation therapy of multiple myeloma with thalidomide-dexamethasone after intensive chemotherapy
16. Asymptomatic Waldenstrom's macroglobulinemia
17. Consolidation therapy of multiple myeloma withthalidomide–dexamethasone after intensive chemotherapy
18. Recent advances in treatment of multiple myeloma and Waldenström’s macroglobulinemia
19. Erratum: International uniform response criteria for multiple myeloma
20. Erratum: International uniform response criteria for multiple myeloma
21. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib:A multicenter international myeloma working group study
22. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib
23. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
24. Characteristics of Myeloma (MM) Patients (pts) with Central Nervous System (CNS) Involvement
25. The role of vertebral augmentation in multiple myeloma: International Myeloma Working Group Consensus Statement
26. Effect of Len/Dex in MM despite Thal resistance
27. Prognostic significance of magnetic resonance imaging of bone marrow in previously untreated patients with multiple myeloma
28. Treatment of Waldenstrom's macroglobulinemia with rituximab: Prognostic factors for response and progression
29. Prognostic significance of magnetic resonance imaging (MRI) of bone marrow in previously untreated patients with multiple myeloma
30. Asymptomatic Waldenstrom's macroglobulinemia
31. Asymptomatic Waldenstrom's disease
32. Impact of complete remission with intensive therapy in patients with responsive multiple myeloma
33. High-dose chemotherapy followed by stem cell transplantation in patients with resistant Waldenstrom's macroglobulinemia
34. High-dose chemotherapy - High-dose chemotherapy followed by stem cell transplantation in patients with resistant Waldenstrom's macroglobulinemia
35. A decade of experience: Primary treatment of Waldenstrom's macroglobulinemia (WM) with 2-chlorodeoxyadenosine (2-CDA) alone or in combination
36. Imaging of myeloma bone disease: Implications for staging, prognosis and follow-up
37. Impact of complete remission after ablative therapy for multiple myeloma
38. Prognostic significance of magnetic resonance imaging (MRI) of bone marrow in previously untreated patients with multiple myeloma
39. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: An overview of 6,633 patients from 27 randomized trials
40. Magnetic resonance imaging of the bone marrow in plasma cell dyscrasias
41. Value of novel agents and intensive therapy for patients with multiple myeloma
42. Limited primary therapy for multiple myeloma followed by maintenance with alpha interferon or dexamethasone
43. Myeloablative treatment for multiple myeloma
44. Treatment of Waldenstrom's macroglobulinemia resistant to standard therapy with 2-chlorodeoxyadenosine: identification of prognostic factors
45. HyperCVAD for VAD-resistant multiple myeloma
46. PROGNOSTIC-SIGNIFICANCE OF MAGNETIC-RESONANCE-IMAGING (MRI) IN ASYMPTOMATIC MULTIPLE-MYELOMA
47. Primary plasma cell leukemia
48. PRIMARY PLASMA-CELL LEUKEMIA
49. Outcome and prognostic factors in solitary plasmacytoma.
50. Rapid control of previously untreated multiple myeloma with bortezomib–lenalidomide–dexamethasone (BLD)
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.